NCT03844750 2025-12-31
Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases
University of California, San Francisco
Phase 2 Terminated
Clinical Trials
9 trialsNCT05400122 2025-11-12
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
Case Comprehensive Cancer Center
Phase 1 Suspended
NCT04103645 2025-07-02
Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN Patients
Weill Medical College of Cornell University
Phase 2 Terminated
NCT05588648 2025-04-10
Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma
MedPacto, Inc.
Phase 1/2 Recruiting
NCT04515979 2024-12-09
Vactosertib in Combination with Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) Subjects
MedPacto, Inc.
Phase 2 Terminated
NCT03143985 2024-05-24
Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma
Case Comprehensive Cancer Center
Phase 1 Completed
NCT04893252 2022-11-30
Vactosertib and Durvalumab in Gastric Cancer
National Cancer Center, Korea
Phase 2 Unknown
NCT04258072 2022-06-15
Vactosertib With Nal-IRI/FL in Metastatic Pancreatic Ductal Adenocarcinoma.
Samsung Medical Center
Phase 1 Unknown
NCT04656002 2022-06-15
As a Second-line Treatment for Metastatic Gastric Adenocarcinoma Patients, the Safety and Effective of Vactosertib Administration in Combination With Paclitaxel+Ramucirumab is Evaluated, and a Phase 2a Clinical Trial to Biomarkers
Samsung Medical Center
Phase 2 Unknown